Parallel Advisors, LLC Biomarin Pharmaceutical Inc Transaction History

Parallel Advisors, LLC

  • $4.87 Billion
  • Q2 2025

A detailed history of Parallel Advisors, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 474 shares of BMRN stock, worth $27,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares
474
Previous 1,335 64.49%
Holding current value
$27,875
Previous $94,000 72.34%
% of portfolio
0.0%
Previous 0.0%

Shares

35 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 07, 2025
SELL
$54.08 - $68.32 $46,562 - $58,823
-861 Reduced 64.49%
474 $26,000
Q1 2025

Apr 07, 2025
BUY
$61.25 - $72.83 $40,425 - $48,067
660 Added 97.78%
1,335 $94,000
Q4 2024

Feb 10, 2025
SELL
$61.93 - $70.49 $24,462 - $27,843
-395 Reduced 36.92%
675 $44,000
Q3 2024

Nov 13, 2024
SELL
$69.02 - $93.84 $73,437 - $99,845
-1,064 Reduced 49.86%
1,070 $75,000
Q2 2024

Aug 08, 2024
SELL
$74.43 - $92.22 $17,342 - $21,487
-233 Reduced 9.84%
2,134 $175,000
Q1 2024

May 06, 2024
BUY
$83.81 - $99.0 $14,163 - $16,731
169 Added 7.69%
2,367 $206,000
Q4 2023

Feb 09, 2024
SELL
$76.22 - $98.51 $11,737 - $15,170
-154 Reduced 6.55%
2,198 $211,000
Q3 2023

May 20, 2024
SELL
$85.07 - $94.48 $260,484 - $289,297
-3,062 Reduced 56.56%
2,352 $208,000
Q3 2023

Nov 13, 2023
SELL
$85.07 - $94.48 $260,484 - $289,297
-3,062 Reduced 56.56%
2,352 $208,000
Q2 2023

May 20, 2024
SELL
$86.68 - $100.3 $52,354 - $60,581
-604 Reduced 10.04%
5,414 $469,000
Q2 2023

Aug 04, 2023
SELL
$86.68 - $100.3 $52,354 - $60,581
-604 Reduced 10.04%
5,414 $469,000
Q1 2023

May 20, 2024
BUY
$87.74 - $117.27 $320,338 - $428,152
3,651 Added 154.25%
6,018 $585,000
Q1 2023

Apr 25, 2023
BUY
$87.74 - $117.27 $91,776 - $122,664
1,046 Added 21.04%
6,018 $585,000
Q4 2022

Feb 03, 2023
BUY
$80.93 - $108.63 $35,528 - $47,688
439 Added 9.68%
4,972 $514,000
Q3 2022

Nov 10, 2022
BUY
$82.16 - $96.94 $270,224 - $318,835
3,289 Added 264.39%
4,533 $384,000
Q2 2022

Aug 01, 2022
BUY
$71.48 - $86.85 $2,072 - $2,518
29 Added 2.39%
1,244 $103,000
Q1 2022

Apr 28, 2022
SELL
$74.28 - $92.69 $19,461 - $24,284
-262 Reduced 17.74%
1,215 $95,000
Q4 2021

Jan 20, 2022
BUY
$71.72 - $91.47 $53,790 - $68,602
750 Added 103.16%
1,477 $130,000
Q3 2021

Nov 02, 2021
BUY
$74.77 - $85.47 $2,392 - $2,735
32 Added 4.6%
727 $56,000
Q2 2021

Aug 06, 2021
BUY
$75.51 - $84.79 $8,834 - $9,920
117 Added 20.24%
695 $58,000
Q4 2020

Feb 02, 2021
SELL
$72.61 - $90.2 $9,076 - $11,275
-125 Reduced 17.78%
578 $51,000
Q3 2020

Oct 27, 2020
BUY
$71.87 - $131.03 $15,883 - $28,957
221 Added 45.85%
703 $53,000
Q2 2020

Jul 16, 2020
BUY
$79.55 - $124.22 $5,966 - $9,316
75 Added 18.43%
482 $59,000
Q1 2020

Apr 27, 2020
BUY
$71.37 - $96.85 $2,355 - $3,196
33 Added 8.82%
407 $34,000
Q3 2019

Nov 01, 2019
BUY
$67.4 - $85.11 $1,415 - $1,787
21 Added 5.95%
374 $25,000
Q2 2019

Aug 05, 2019
SELL
$80.35 - $93.9 $5,222 - $6,103
-65 Reduced 15.55%
353 $30,000
Q1 2019

May 01, 2019
SELL
$84.2 - $98.62 $4,799 - $5,621
-57 Reduced 12.0%
418 $37,000
Q4 2018

Feb 05, 2019
SELL
$80.14 - $106.07 $240,660 - $318,528
-3,003 Reduced 86.34%
475 $40,000
Q3 2018

Nov 01, 2018
BUY
$93.92 - $105.72 $46,960 - $52,860
500 Added 16.79%
3,478 $337,000
Q2 2018

Jul 30, 2018
BUY
$76.01 - $99.03 $151,487 - $197,366
1,993 Added 202.34%
2,978 $280,000
Q1 2018

May 08, 2018
SELL
$77.67 - $92.63 $3,961 - $4,724
-51 Reduced 4.92%
985 $80,000
Q4 2017

Feb 13, 2018
BUY
$80.76 - $95.13 $3,553 - $4,185
44 Added 4.44%
1,036 $92,000
Q3 2017

Nov 15, 2017
BUY
$80.6 - $94.95 $79,955 - $94,190
992 New
992 $80,000
Q3 2017

Nov 14, 2017
SELL
$80.6 - $94.95 $82,856 - $97,608
-1,028 Closed
0 $0
Q2 2017

Aug 07, 2017
BUY
N/A
1,028
1,028 $90,000

Others Institutions Holding BMRN

# of Institutions
670
Shares Held
185M
Call Options Held
1.25M
Put Options Held
992K
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $10.9B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email